The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Insights from the ItaLynch study for optimizing Lynch syndrome diagnosis
Alberto Puccini, MD, IRCCS Humanitas Research Hospital, Milan, Italy, discusses the diagnostic pathway for Lynch syndrome, a common hereditary cause of colorectal cancer due to germline mutations in DNA mismatch repair (MMR) genes. Despite international guidelines, Lynch syndrome remains largely undiagnosed globally. In some countries, MMR deficiency testing is now part of adjuvant and neoadjuvant care. Reflex testing for MLH1 loss, followed by BRAF and MLH1 hypermethylation tests, reduces genetic counselling needs and improves germline testing accuracy. This approach is being explored in the observational ItaLynch study, which aims to validate a new diagnostic algorithm for selecting patients for genetic testing. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
